Navigation Links
Seattle Genetics Highlights Data on its Proprietary Antibody-Drug,Conjugate Technology at AACR

BOTHELL, Wash. & LOS ANGELES--(BUSINESS WIRE)--Apr 17, 2007 - Seattle Genetics, Inc. (Nasdaq: SGEN) today announced data from fifteen presentations by the company and its collaborators at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) demonstrating preclinical advances with its proprietary antibody-drug conjugate (ADC) technology and cancer product pipeline.

ADCs are monoclonal antibodies linked to cell-killing drugs. Seattle Genetics' ADC technology employs synthetic, highly potent drugs that are bound to monoclonal antibodies through proprietary linker systems. The linkers are designed to be stable in the bloodstream but to release the drug payload under specific conditions once inside target cells, thereby sparing non-target cells many of the toxic effects of traditional chemotherapy.

"Empowered antibodies utilizing our ADC technology have the potential to significantly impact the way cancer is treated," said Clay B. Siegall, Ph.D., President and Chief Executive Officer at Seattle Genetics. "Our strong presence at AACR this year reflects continued progress with our proprietary and partnered ADC programs. We expect to report clinical data from the ongoing phase I dose-escalation trial of SGN-35, our lead ADC, later this year, while both we and our collaborators continue to advance additional ADC programs into and towards the clinic."

ADC Programs

Researchers reported preclinical data at AACR describing how changes in the structure of the attached drugs can affect ADC efficacy and tolerability, the impact that linker structure and these modifications can have on ADC activity, and the ability of Seattle Genetics' ADC technology to effectively deliver active drugs to target tissue while avoiding non-targeted drug release. (Abstracts #4793, #916 and #4088) Further data from preclinical models of ADCs provide mechanistic insight into how and when drugs are r
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
2. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
3. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
6. Myriad Genetics Presents Tumor Origin Technology at AACR
7. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
8. Myriad Genetics Presents Azixas Mode of Action at AACR
9. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
Post Your Comments:
(Date:1/23/2015)...  Pete Rose, baseball,s all-time hits leader, is the new spokesperson ... Ducere Pharma has announced. "Pete,s a Hall of ... him on board with Myoflex," said Ducere Pharma Chief Executive ... who is known across all generations. The passion and intensity ...
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: ... Phase I trial of Lixte,s lead compound, LB‑100, is being ... John S. Kovach , M.D., the founder and ... to be completed at a single site. Accrual of patients, ...
(Date:1/23/2015)... plc (NYSE: MNK ) announced today that ... program. The open-ended authorization permits the company to repurchase ... "Funding additional initiatives and seeking attractive ... to pursue a range of focused growth strategies," said ...
Breaking Medicine Technology:Pete Rose bets on Myoflex to relieve aches and pains 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... 24,544 terms, including genetic testing and device software , ... PLYMOUTH MEETING, Pa. , July 8 ... the expansion of its database to include thousands of new terms for medical devices, ... , , The ...
... FRANCISCO, Calif. , July 8 iPierian, ... stem cells (iPSCs) for drug discovery, today announced the ... equity financing.  The financing round was led by new ... Capital and ATEL Ventures.  All current investors also participated, ...
Cached Medicine Technology:ECRI Institute Adds 4,000 New Terms to Universal Medical Device Nomenclature System™ 2ECRI Institute Adds 4,000 New Terms to Universal Medical Device Nomenclature System™ 3ECRI Institute Adds 4,000 New Terms to Universal Medical Device Nomenclature System™ 4iPierian Closes $22 Million Series B Financing Led By Google Ventures 2iPierian Closes $22 Million Series B Financing Led By Google Ventures 3
(Date:1/22/2015)... 2015 Padre Murphy's and Owner Tom Boyle ... Pro Player Health Alliance (PPHA). The PPHA's passion for ... everyone, including NFL greats, treated for obstructive sleep apnea (OSA) ... supporting the cause in the valley. The most recent plans ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently ... View website of AngelWeddingDress.com to find more details. ... online for a bridal party. AngelWeddingDress offers a variety ... Its maternity wedding dresses are specially designed for 2015. ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining the ... . , Auto insurance quotes help many drivers find ... necessary to call an agent or visit an agency for ... single website: http://autocarinsurancebest.com/ . , Every business who relies ...
(Date:1/22/2015)... 2015 Yesterday, Senator Holly Mitchell ... Kristin Olsen (R-Modesto) were honored by the California ... biotechnology, biomedical science, medical device and pharmaceutical innovation ... the “2014 Life Sciences Champion” award from CHI ...
(Date:1/22/2015)... 22, 2015 EBSCO Information Services ... expanding their relationship in an effort to further promote visibility ... While EBSCO has long made AMA journals available via its ... for The JAMA Network. , Long known as ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... about microRNAs short strands of RNA that can ... it becomes how closely they are associated with cancer. ... and their colleagues have identified two microRNAs (miRNAs) that ... miRNAs may provide an early warning of metastatic breast ...
... findings apply to humans , , MONDAY, Jan. 28 (HealthDay News) ... a new study found. , The mice that were breast-fed ... the allergen and developed tolerance to it. , But once ... can be extrapolated to humans. , "You hate to ...
... 28 MaxCyte, Inc., a,clinical-stage therapeutic company ... systems, announces that Madhusudan V. Peshwa, Ph.D., ... present on Tuesday,January 29, 2008, at 11:35 ... Therapy,Forum in Washington, DC. Dr. Peshwa,s presentation ...
... of,President Bush,s final State of the Union address this ... that,should be undertaken this year to protect our nation,s ... unstable economy, the growing health,care crisis and very real ... on the president and Congress to:, -- Increase ...
... A new study, led by researchers at The ... that certain over-the-counter earwax softeners can cause severe inflammation ... results of the study, recently published in The Laryngoscope, ... , Patients often complain that wax is blocking their ...
... Preventive Medicine (ACPM) has found there is insufficient ... prostate screening with digital rectal examination (DRE) or ... (PSA). ACPM advises that clinicians caring for ... family history, should provide information about the potential ...
Cached Medicine News:Health News:2 microRNAs promote spread of tumor cells 2Health News:2 microRNAs promote spread of tumor cells 3Health News:Breast-Feeding Protected Mice From Asthma 2Health News:Breast-Feeding Protected Mice From Asthma 3Health News:MaxCyte to Present at the Phacilitate Cell and Gene Therapy Forum 2008 2Health News:APHA Says Investing in Healthy People and Communities Can Help Create a Healthy Economy 2
... Designed and manufactured specifically ... MultiWash II delivers the ... demand. The MultiWash II ... dependable accuracy, while providing ...
... the determination of A1c is also designed to ... is a fully automated analyzer including primary tube ... in safety and positive identification. The analysis methodology ... be interference-free and to produce the lowest CV's ...
Micromat II Hemoglobin A1c instrument is an easy-to-use, accurate and precise instrument with an requirement of only 10 L of capillary or venous sample....
... Cascade M-4 is a manual hemostasis ... routine clotting assays - PTs, aPTTs, ... for easy, inexpensive, low-volume testing, this ... big on features, offering time and ...
Medicine Products: